close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about Respiratory syncytial virus

Recent news which mentions Respiratory syncytial virus

Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
Tags Health & Science AstraZeneca PLC Sanofi SA
From CNBC.com News
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
Tags Pfizer Inc Business GSK plc
From CNBC.com News
Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
Tags GSK plc Business Pfizer Inc
From CNBC.com News
RSV vaccine from GSK shows potential to protect adults 50 to 59
Tags Immunizations Business News Pharmaceuticals
From CNBC.com News
CDC advisors recommend Pfizer maternal RSV vaccine to protect infants
Tags Breaking news Biotech and Pharmaceuticals Business
From CNBC.com News
FDA approves Pfizer maternal RSV vaccine for infants
Tags Breaking news Biotech and Pharmaceuticals Business
From CNBC.com News
GSK sues Pfizer in U.S. court for patent infringement over RSV vaccine
Tags Respiratory syncytial virus Pharmaceuticals Companies
From CNBC.com News
GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales
Tags Health & Science Biotechnology US: News
From CNBC.com News
CDC recommends RSV vaccines from Pfizer, GSK for adults 60 and older
Tags Business News Immunizations Social issues
From CNBC.com News
Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says
Tags Pharmaceuticals Respiratory syncytial virus Social issues
From CNBC.com News
CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults over 60
Tags Health care industry Companies Social issues
From CNBC.com News
GSK says RSV vaccine for older adults provides protection over two seasons
Tags Breaking news Biotech and Pharmaceuticals GSK plc
From CNBC.com News
Pfizer RSV vaccine for older adults is only slightly less effective after 18 months
Tags Health care industry Companies Pharmaceuticals
From CNBC.com News
FDA approves Pfizer RSV vaccine for older adults
Tags Breaking News: Business Biotech and Pharmaceuticals U/S/ Economy
From CNBC.com News
Here’s what Pfizer and Moderna say is next for their Covid vaccines
Tags BioNTech SE Biotech and Pharmaceuticals Business
From CNBC.com News
FDA advisors recommend Pfizer’s RSV vaccine for infants but raise safety concerns
Tags US: News Biotechnology Health & Science
From CNBC.com News
Pfizer RSV vaccine for infants has 'generally favorable' safety data, FDA staff say
Tags Business Pfizer Inc Vaccinations
From CNBC.com News
FDA approves GSK's RSV vaccine for older adults, world's first shot against virus
Tags Coronavirus US: News Biotechnology
From CNBC.com News
FDA says Guillain-Barre syndrome is possible risk of Pfizer's RSV vaccine for older adults
Tags Business News Policy Pandemics
From CNBC.com News
Moderna, Pfizer's new race: The RSV vaccine FDA approval process
Tags Immunizations Technology CNBC Disruptor 50
From CNBC.com News
A nutritionist shares the best snacks to bring on a plane to boost your immune system
Tickers LIFE
Tags Hospitality and leisure industry Respiratory syncytial virus COVID/19
From CNBC.com News
Why flu season is so bad this year
Tickers LIFE
Tags Children Biotech and Pharmaceuticals U/S/ Economy
From CNBC.com News
Pfizer RSV vaccine given to pregnant mothers is effective at protecting newborns, company's data shows
Tags Business Epidemics Pfizer Inc
From CNBC.com News
Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV
Tickers AZN AZNCF SNY
Tags REspiratory syncytial virus AZNCF Biotech
From Benzinga
Pfizer's RSV Vaccine Candidate Receives FDA Breakthrough Therapy Tag For Prevention of RSV In Older Adults
Tickers PFE
Tags General Benzinga PFE
From Benzinga
Johnson & Johnson Posts Additional RSV Vaccine Data
Tickers JNJ
Tags Health Care Biotech REspiratory syncytial virus
From Benzinga
J&J's RSV Vaccine Candidate Shows 80% Efficacy In Older Adults
Tickers JNJ
Tags JNJ General Benzinga
From Benzinga
Pfizer Starts Late-Stage Trial For RSV Vaccine Candidate In Older Patients
Tickers PFE
Tags Phase 3 Trial Briefs REspiratory syncytial virus
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today